3-MeO-PCMo

3-MeO-PCMo
IUPAC ime
	4-[1-(3-metoksifenil)cikloheksil]morfolin
Pravni status
Pravni status	CA: Plan I ; DE: NpSG ; UK: PSA ;
Identifikatori
CAS broj	138873-80-0
PubChem	CID 132605908
ChemSpider	58191437
UNII	96QW73BA62
Hemijski podaci
Formula	C17H25NO2
Molarna masa	275,39 g·mol−1
	SMILES COC1=CC(C2(N3CCOCC3)CCCCC2)=CC=C1; ;
	InChI InChI=1S/C17H25NO2/c1-19-16-7-5-6-15(14-16)17(8-3-2-4-9-17)18-10-12-20-13-11-18/h5-7,14H,2-4,8-13H2,1H3; Key:BOGOEDFWPOXWQE-UHFFFAOYSA-N;

3-MeO-PCMo je disocijativni anestetik koji je po strukturi sličan fenciklidinu^[1]^[2] i koji se prodaje onlajn kao dizajnirana droga.^[3]^[4] Inhibitorni efekat 3-MeO-PCMo na smanjenje gustine klastera drebrina NMDAR stimulacijom glutaminskom kiselinom je niži od PCP-a ili 3-MeO-PCP, sa polovinom maksimalne inhibitorne koncentracije (IC₅₀) od 26,67 μM (3-MeO-PCMo), 2,02 μM (PCP) i 1,51 μM (3-MeO-PCP).^[5]

^ Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (април 2011). „New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats”. Pharmacology, Biochemistry, and Behavior. 98 (2): 227—33. PMID 21215770. S2CID 24650035. doi:10.1016/j.pbb.2010.12.019.
^ Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (март 2020). „4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels”. Psychopharmacology. 237 (3): 757—772. PMID 31828394. S2CID 209169410. doi:10.1007/s00213-019-05412-y.
^ Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (фебруар 2018). „Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues”. Drug Testing and Analysis. 10 (2): 272—283. PMID 28513099. doi:10.1002/dta.2213.
^ „3-MeO-PCMo”. New Synthetic Drugs Database. Архивирано из оригинала 2016-07-03. г. Приступљено 2016-02-09.
^ Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (2019). „Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay”. Journal of Pharmacological and Toxicological Methods. 99: 106583. PMID 31082488. doi:10.1016/j.vascn.2019.106583 .

[1] Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (април 2011). „New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats”. Pharmacology, Biochemistry, and Behavior. 98 (2): 227—33. PMID 21215770. S2CID 24650035. doi:10.1016/j.pbb.2010.12.019.

[2] Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (март 2020). „4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels”. Psychopharmacology. 237 (3): 757—772. PMID 31828394. S2CID 209169410. doi:10.1007/s00213-019-05412-y.

[3] Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (фебруар 2018). „Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues”. Drug Testing and Analysis. 10 (2): 272—283. PMID 28513099. doi:10.1002/dta.2213.

[4] „3-MeO-PCMo”. New Synthetic Drugs Database. Архивирано из оригинала 2016-07-03. г. Приступљено 2016-02-09.

[5] Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (2019). „Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay”. Journal of Pharmacological and Toxicological Methods. 99: 106583. PMID 31082488. doi:10.1016/j.vascn.2019.106583 .

[1]

[2]

[3]

[4]

[5]